Parallel Advisors LLC Has $42,000 Holdings in Smith & Nephew plc (NYSE:SNN)

Parallel Advisors LLC lifted its stake in Smith & Nephew plc (NYSE:SNNFree Report) by 150.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,533 shares of the medical equipment provider’s stock after purchasing an additional 922 shares during the quarter. Parallel Advisors LLC’s holdings in Smith & Nephew were worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Scharf Investments LLC increased its holdings in Smith & Nephew by 20.5% in the fourth quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider’s stock worth $81,304,000 after buying an additional 506,474 shares during the last quarter. American Century Companies Inc. increased its position in Smith & Nephew by 343.5% during the third quarter. American Century Companies Inc. now owns 2,364,037 shares of the medical equipment provider’s stock worth $58,557,000 after buying an additional 1,830,965 shares during the last quarter. Brandes Investment Partners LP bought a new position in Smith & Nephew during the fourth quarter valued at about $29,884,000. Wells Fargo & Company MN boosted its stake in shares of Smith & Nephew by 20.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after acquiring an additional 173,448 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of Smith & Nephew by 56.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 649,795 shares of the medical equipment provider’s stock valued at $16,095,000 after acquiring an additional 235,658 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on SNN shares. StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 13th. UBS Group raised Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Read Our Latest Stock Analysis on Smith & Nephew

Smith & Nephew Stock Down 0.5 %

Shares of Smith & Nephew stock opened at $26.34 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.77 and a quick ratio of 0.72. The firm has a fifty day moving average price of $24.85 and a two-hundred day moving average price of $26.33. Smith & Nephew plc has a fifty-two week low of $21.52 and a fifty-two week high of $32.28.

About Smith & Nephew

(Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

See Also

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNNFree Report).

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.